The role of amylin and related peptides in osteoporosis

Clinica Chimica Acta

Volumn 373, Issue 1-2, 2006, Pages 9-16

  Bronský, Jiří ^a   Průša, Richard ^a   Nevoral, Jiří ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Adrenomedullin; Amylin; Calcitonin; Calcitonin gene related peptide; Islet amyloid polypeptide; Osteoporosis

Indexed keywords

ADRENOMEDULLIN; ALENDRONIC ACID; AMYLIN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN RECEPTOR; ESTROGEN; ETIDRONIC ACID; PRAMLINTIDE; RALOXIFENE; RECEPTOR ACTIVITY MODIFYING PROTEIN; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

AGING; AMINO ACID SEQUENCE; BONE DEVELOPMENT; BONE METABOLISM; BONE MINERAL; CALCIUM DEFICIENCY; CELL MATURATION; CELL PROLIFERATION; CELL STIMULATION; COMORBIDITY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FRAGILITY FRACTURE; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HORMONE RELEASE; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

AMYLOID; ANIMALS; BONE AND BONES; CALCITONIN; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; ISLET AMYLOID POLYPEPTIDE; OSTEOPOROSIS; PEPTIDES;

ANIMALIA;

EID: 33748625982     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.05.009     Document Type: Review

References (94)

1. Dennison E., Cole Z., and Cooper C. Diagnosis and epidemiology of osteoporosis. Curr Opin Rheumatol 17 (2005) 456-461
2. Werner P. Knowledge about osteoporosis: assessment, correlates and outcomes. Osteoporos Int 16 (2005) 115-127
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis and therapy. JAMA 285 (2001) 785-795
4. Ralston S.H. Genetic determinants of osteoporosis. Curr Opin Rheumatol 17 (2005) 475-479
5. Amir G., Rosemann E., Sherman Y., Greenfels Z., Ne'eman Z., and Cohen A.M. Osteoporosis in the Cohen diabetic rat: correlation between histomorphometric changes in bone and microangiopathy. Lab Invest 82 (2002) 1399-1405
6. Vogt M.T., Cauley J.A., Kuller L.H., and Nevitt M.C. Bone mineral density and blood flow to the lower extremities: the study of osteoporotic fractures. J Bone Miner Res 12 (1997) 283-289
7. Gunczler P., Lanes R., Raz-Martinez V., et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 11 (1998) 413-419
8. Hui S.L., Epstein S., and Johnston Jr. C.C. A prospective study of bone mass in patients with type I diabetes. J Clin Endocrinol Metab 60 (1985) 74-80
9. Kemink S.A., Hermus A.R., Swinkels L.M., Lutterman J.A., and Smals A.G. Osteopenia in insulin-dependent diabetes mellitus; prevalence and aspects of pathophysiology. J Endocrinol Invest 23 (2000) 295-303
10. Inzerillo A.M., and Epstein S. Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5 (2004) 261-268
11. Schwartz A.V. Diabetes mellitus: does it affect bone?. Calcif Tissue Int 73 (2003) 515-519
12. Leidig-Bruckner G., and Ziegler R. Diabetes mellitus a risk for osteoporosis?. Exp Clin Endocrinol Diabetes 109 (2001) S493-S514
13. El Miedany Y.M., el Gaafary S., and el Baddini M.A. Osteoporosis in older adults with non-insulin-dependent diabetes mellitus: is it sex related?. Clin Exp Rheumatol 17 (1999) 561-567
14. Forsen L., Meyer H.E., Midthjell K., and Edna T.H. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 42 (1999) 920-925
15. Shires R., Teitelbaum S.L., Bergfeld M.A., Fallon M.D., Slatopolsky E., and Avioli L.V. The effect of streptozotocin-induced chronic diabetes mellitus on bone and mineral homeostasis in the rat. J Lab Clin Med 97 (1981) 231-240
16. Goodman W.G., and Hori M.T. Diminished bone formation in experimental diabetes. Relationship to osteoid maturation and mineralization. Diabetes 33 (1984) 825-831
17. Mishima N., Sahara N., Shirakawa M., and Ozawa H. Effect of streptozotocin-induced diabetes mellitus on alveolar bone deposition in the rat. Arch Oral Biol 47 (2002) 843-849
18. Bouillon R., Bex M., Van Herck E., et al. Influence of age, sex, and insulin on osteoblast function: osteoblast dysfunction in diabetes mellitus. J Clin Endocrinol Metab 80 (1995) 1194-1202
19. Wu K., Schubeck K.E., Frost H.M., and Villanueva A. Haversian bone formation rates determined by a new method in a mastodon, and in human diabetes mellitus and osteoporosis. Calcif Tissue Res 6 (1970) 204-219
20. Glajchen N., Epstein S., Ismail F., Thomas S., Fallon M., and Chakrabarti S. Bone mineral metabolism in experimental diabetes mellitus: osteocalcin as a measure of bone remodeling. Endocrinology 123 (1988) 290-295
21. Scheiwiller E., Guler H.P., Merryweather J., et al. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature 323 (1986) 169-171
22. Bonfanti R., Mora S., Prinster C., et al. Bone modeling indexes at onset and during the first year of follow-up in insulin-dependent diabetic children. Calcif Tissue Int 60 (1997) 397-400
23. Valerio G., del Puente A., Esposito-del Puente A., Buono P., Mozzillo E., and Franzese A. The lumbar bone mineral density is affected by long-term poor metabolic control in adolescents with type 1 diabetes mellitus. Horm Res 58 (2002) 266-272
24. Malgaroli A., Meldolesi J., Zambonin-Zallone A., and Teti A. Control of cytosolic free calcium in rat and chicken osteoclasts. J Biol Chem 264 (1989) 14342-14347
25. Zaidi M., Datta H.K., Patchell A., Moonga B.S., and MacIntyre I. Calcium-activated intracellular calcium elevation: a novel mechanism of osteoclast regulation. Biochem Biophys Res Commun 163 (1989) 1461-1465
26. Zaidi M., Pazianas M., Shankar V.S., et al. Osteoclast function and its control. Exp Physiol 78 (1993) 721-739
27. Katafuchi T., and Minamino N. Structure and biological properties of three calcitonin receptor-stimulating peptides, novel members of the calcitonin gene-related peptide family. Peptides 25 (2004) 2039-2045
28. Chang C.L., Roh J., and Hsu S.Y. Intermedin, a novel calcitonin family peptide that exists in teleosts as well as in mammals: a comparison with other calcitonin/intermedin family peptides in vertebrates. Peptides 25 (2004) 1633-1642
29. Cornish J., and Naot D. Amylin and adrenomedullin: novel regulators of bone growth. Curr Pharm Des 8 (2002) 2009-2021
30. Nicholson C.G., Moseley J.M., Sexton P.M., Mendelsohn F.A.O., and Martin T.J. Abundant calcitonin receptors in isolated rat osteoclasts. Biochemical and autoradiographic characterisation. J Clin Invest 78 (1986) 355-360
31. Anderson R.E., Woodbury D.M., and Jee W.S.S. Humoral and ionic regulation of osteoclast acidity. Calcif Tissue Int 39 (1986) 252-258
32. Chambers T.J., Fuller K., and Darby J.A. Hormonal regulation of acid phosphatase release by osteoclasts disaggregated from neonatal rat bone. J Cell Physiol 132 (1987) 90-96
33. Chambers T.J., and Magnus C.J. Calcitonin alters behaviour of isolated osteoclasts. J Pathol 36 (1982) 27-39
34. Chambers T.J., McSheehy P.M.J., Thomson B.M., and Fuller K. The effect of calcium regulating hormones and prostaglandins on the bone resorption by osteoclasts disaggregated from rabbit long bones. Endocrinology 116 (1985) 234-239
35. Chambers T.J., and Ali N.N. Inhibition of osteoclastic motility by prostaglandins I2, E1, E2 and 6-oxo-E1. J Pathol 139 (1983) 383-398
36. Lin H.Y., Harris T.L., Flannery N.S., et al. Expression cloning of an adenylate cyclase-coupled calcitonin receptor. Science 254 (1991) 1022-1024
37. Sexton P.M., Houssami S., Hilton J.M., et al. Identification of brain isoforms of the rat calcitonin receptor. Mol Endocrinol 7 (1993) 815-821
38. Njuki F., Nicholl C.G., Howard A., et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci 85 (1993) 385-388
39. Force T., Bonventre J.V., Flannery M.R., Gorn A.H., Yamin M., and Goldring S.R. A cloned porcine renal calcitonin receptor couples to adenylyl cyclase and phospholipase C. Am J Physiol 262 (1992) F1110-F1115
40. Naro F., Perez M., Migliaccio S., et al. Phospholipase D- and protein kinase C isoenzyme-dependent signal transduction pathways activated by the calcitonin receptor. Endocrinology 139 (1998) 3241-3248
41. McLatchie L.M., Fraser N.J., Main M.J., et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 393 (1998) 333-339
42. Zaidi M., Fuller K., Bevis P.J.R., Gaines Das R.E., Chambers T.J., and McIntyre I. Calcitonin gene-related peptide inhibits osteoblastic bone resorption: a comparative study. Calcif Tissue Int 40 (1987) 149-154
43. Hay D.L., Conner A.C., Howitt S.G., et al. The pharmacology of CGRP-responsive receptors in cultured and transfected cells. Peptides 25 (2004) 2019-2026
44. Brain S.D., and Grant A.D. Vascular actions of calcitonin gene-related peptide and adrenomedullin. Physiol Rev 84 (2004) 903-934
45. Cornish J., Callon K.E., Lin C.Q., et al. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. Bone Miner Res 14 (1999) 1302-1309
46. Hoff A.O., Catala-Lehnen P., Thomas P.M., et al. Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110 (2002) 1849-1857
47. Kitamura K., Kangawa K., Kawamoto M., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (1993) 553-560
48. Montuenga L.M., Martinez A., Miller M.J., Unsworth E.J., and Cuttitta F. Expression of adrenomedullin and its receptor during embryogenesis suggests autocrine or paracrine modes of action. Endocrinology 138 (1997) 440-451
49. Naot D., Callon K.E., Grey A., Cooper G.J.S., Reid I., and Cornish J. A potential role for adrenomedullin as a local regulator of bone growth. Endocrinology 142 (2001) 1849-1857
50. Kubo A., Minamino N., Isumi Y., et al. Production of adrenomedullin in macrophage cell line and peritoneal macrophage. J Biol Chem 273 (1998) 16730-16738
51. Cornish J., Callon K.E., Cooper G.J., and Reid I.R. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 207 (1995) 133-139
52. Cornish J., Callon K.E., Coy D.H., et al. Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. Am J Physiol 273 (1997) E1113-E1120
53. Cornish J., Callon K.E., Bava U., et al. Systemic administration of adrenomedullin(27-52) increases bone volume and strength in male mice. J Endocrinol 170 (2001) 251-257
54. Cooper G.J., Willis A.C., Clark A., Turner R.C., Sim R.B., and Reid K.B. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 84 (1987) 8628-8632
55. German M.S., Moss L.G., Wang J., and Rutter W.J. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes. Mol Cell Biol 12 (1992) 1777-1788
56. Higham C.E., Hull R.L., Lawrie L., et al. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267 (2000) 4998-5004
57. Wimalawansa S.J. Amylin, calcitonin gene-related peptide, calcitonin, and adrenomedullin: a peptide superfamily. Crit Rev Neurobiol 11 (1997) 167-239
58. Chin S.Y., Hall J.M., Brain S.D., and Morton I.K. Vasodilator responses to calcitonin gene-related peptide (CGRP) and amylin in the rat isolated perfused kidney are mediated via CGRP1 receptors. J Pharmacol Exp Ther 269 (1994) 989-992
59. Wookey P.J., Tikellis C., Du H.-C., Qin H.-F., Sexton P.M., and Cooper M.E. Amylin binding on rat renal cortex, stimulation of adenylyl cyclase and activation of plasma renin. Am J Physiol 270 (1996) 289-294
60. Christopoulos G., Perry K., Morfis M., et al. Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product. Mol Pharmacol 56 (1999) 235-242
61. Harris P.J., Cooper M.E., Hiranyachattada S., et al. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Am J Physiol 272 (1997) F13-F21
62. Riediger T., Rauch M., and Schmid H. Actions of amylin on subfornical organ neurons and on drinking behaviour in rats. Am J Physiol 276 (1999) R514-R521
63. Riediger T., Schmid H., Young A., and Simon E. Pharmacological characterization of amylin-related peptides activating subfornical organ neurons. Brain Res 837 (1999) 161-168
64. Lutz T., Senn M., Althaus J., Delprete E., Ehrensperger F., and Scharrer E. Lesion of the area postrema nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CFRP) in rats. Peptides 19 (1998) 309-317
65. Young A. Amylin's physiology and its role in diabetes. Curr Opin Endocrinol Diabetes 4 (1997) 282-290
66. Percy A.J., Trainor D.A., Rittenhouse J., Phelps J., and Koda J.E. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42 (1996) 576-585
67. Butler P.C., Chou J., Carter W.B., et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 39 (1990) 752-756
68. Morley J.E., and Flood F. Amylin decreases food intake in mice. Peptides 12 (1991) 865-869
69. Wookey P.J., Xuereb L., Tikellis C., and Cooper M.E. Amylin in the periphery. Sci World J 3 (2003) 163-175
70. Clementi G., Valerio C., Emmi I., Prato A., and Drago F. Behavioral effects of amylin injected intracerebroventricularly in the rat. Peptides 17 (1996) 589-591
71. Bronsky J., Chada M., Kotaska K., and Prusa R. Amylin-its physiological role in humans. Cesk Fysiol 51 (2002) 176-180
72. Sempoux C., Guiot Y., Dubois D., Moulin P., and Rahier J. Human type 2 diabetes: morphological evidence for abnormal beta-cell function. Diabetes 50 (2001) S172-S177
73. Mulder H., Ekelund M., Ekblad E., and Sundler F. Islet amyloid polypeptide in the gut and pancreas: localization, ontogeny and gut motility effects. Peptides 18 (1997) 771-783
74. Ferrier G., Pierson A., Jones P., Bloom S., Girgis S., and Legon S. Expression of rat amylin (IAPP/DAP) gene. J Mol Endocrinol 3 (1989) R1-R4
75. Wookey P.J., Tikellis C., Nobes M., Casley D., Cooper M.E., and Darby I.A. Amylin as a growth factor during foetal and postnatal development of the rat kidney. Kidney Int 53 (1998) 25-30
76. Guidobono F. Amylin and gastrointestinal activity. Gen Pharmacol 31 (1998) 173-177
77. Rindi G., Terenghi G., Westermark G., Westermark P., Moscoso G., and Polak J.M. Islet amyloid polypeptide in proliferating pancreatic B cells during development, hyperplasia, and neoplasia in humans and mice. Am J Pathol 138 (1991) 1321-1334
78. Datta H.K., Zaidi M., Wimalawansa S.J., et al. In vivo and in vitro effects of amylin and amylin-amide on calcium metabolism in the rat and rabbit. Biochem Biophys Res Commun 162 (1989) 876-881
79. Gilbey S.G., Chatei M.A., Bretherton-Watt D., et al. Islet amyloid polypeptide (IAPP): production by osteoblast cell line and possible role as a paracrine regulator of osteoclas function in man. Clin Sci 81 (1991) 803-808
80. Cornish J., Callon K.E., Lin C., et al. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am J Physiol 274 (1998) E827-E833
81. Villa I., Rubinacci A., Ravasi F., and Guidobono A.F. Effects of amylin on human osteoblast-like cells. Peptides 18 (1997) 537-540
82. Cornish J., Callon K.E., Bava U., Kamona S.A., Cooper G.J., and Reid I.R. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29 (2001) 162-168
83. Owan I., and Ibaraki K. The role of calcitonin gene-related peptide (CGRP) in macrophages: the presence of functional receptors and effects on proliferation and differentiation into osteoclast-like cells. Bone Miner 24 (1994) 151-164
84. Pietschmann P., Farsoudi K.H., Hoffmann O., Klaushofer K., Horandner H., and Peterlik M. Inhibitory effect of amylin on basal and parathyroid hormone-stimulated bone resorption in cultured neonatal mouse calvaria. Bone 14 (1993) 167-172
85. Cornish J., Callon K.E., Gasser J.A., et al. Systemic administration of a novel octapeptide, amylin-(1-8), increases bone volume in male mice. Am J Physiol Endocrinol Metab 279 (2000) E730-E735
86. Cornish J., Callon K.E., King A.R., Cooper G.J.S., and Reid I.R. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol Endocrinol Metab 275 (1998) E694-E699
87. Horcajada-Molteni M.N., Chanteranne B., Lebecque P., et al. Amylin and bone metabolism in streptozotocin-induced diabetic rats. J Bone Miner Res 16 (2001) 958-965
88. Romero D.F., Bryer H.P., Rucinski B., et al. Amylin increases bone volume, but cannot ameliorate diabetic osteopenia. Calcif Tissue Int 56 (1995) 54-61
89. Horcajada-Molteni M.N., Davicco M.J., Lebecque P., Coxam V., Young A.A., and Barlet J.P. Amylin inhibits ovariectomy-induced bone loss in rats. J Endocrinol 165 (2000) 663-668
90. Dechenes C.J., Verchere C.B., Andrikopoulos S., and Kahn S.E. Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol Endocrinol Metab 275 (1998) E785-E791
91. Bronsky J., and Prusa R. Amylin fasting plasma levels are decreased in patients with osteoporosis. Osteoporos Int 15 (2004) 243-247
92. McQueen J. Pramlintide acetate. Am J Health Syst Pharm 62 (2005) 2363-2372
93. Born A.K., Klevesath M.S., Borcea V., et al. The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus. Horm Metab Res 31 (1999) 472-475
94. Hosking D.J., Geusens P., and Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. Q J Med 98 (2005) 403-413